Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto
Kurs
+8,56%
Likviditet
0,26 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-12 | N/A | Bokslutskommuniké 2025 |
| 2025-11-11 | N/A | Kvartalsrapport 2025-Q3 |
| 2025-08-12 | N/A | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | N/A | Årsstämma |
| 2025-05-08 | N/A | Kvartalsrapport 2025-Q1 |
| 2025-02-20 | N/A | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2021-05-25 | - | Kvartalsrapport 2021-Q1 |
| 2020-09-10 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2020-09-09 | - | Årsstämma |
| 2020-06-18 | - | Bokslutskommuniké 2020 |
| 2020-05-14 | - | Extra Bolagsstämma 2020 |
| 2020-03-27 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-30 | - | Kvartalsrapport 2020-Q2 |
| 2019-11-06 | - | Extra Bolagsstämma 2019 |
| 2019-09-27 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2019-09-26 | - | Årsstämma |
| 2019-09-26 | - | Kvartalsrapport 2020-Q1 |
| 2019-07-12 | - | Bokslutskommuniké 2019 |
| 2019-03-01 | - | Kvartalsrapport 2019-Q3 |
| 2018-11-30 | - | Kvartalsrapport 2019-Q2 |
| 2018-09-25 | - | Årsstämma |
| 2018-09-05 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2018-08-31 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-08 | - | Bokslutskommuniké 2018 |
| 2018-03-02 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-01 | - | Kvartalsrapport 2018-Q2 |
| 2017-09-26 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2017-09-25 | - | Årsstämma |
| 2017-09-01 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-08 | - | Bokslutskommuniké 2017 |
| 2017-03-03 | - | Kvartalsrapport 2017-Q3 |
| 2016-12-02 | - | Kvartalsrapport 2017-Q2 |
| 2016-11-21 | - | Extra Bolagsstämma 2016 |
| 2016-09-27 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2016-09-26 | - | Årsstämma |
| 2016-09-02 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-03 | - | Bokslutskommuniké 2016 |
| 2016-03-03 | - | Kvartalsrapport 2016-Q3 |
| 2015-12-03 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-29 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2015-09-28 | - | Årsstämma |
| 2015-09-03 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-04 | - | Bokslutskommuniké 2015 |
| 2015-03-05 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-04 | - | Kvartalsrapport 2015-Q2 |
| 2014-09-30 | - | X-dag ordinarie utdelning |
| 2014-09-29 | - | Årsstämma |
| 2014-09-05 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-05 | - | Bokslutskommuniké 2014 |
| 2014-03-06 | - | Kvartalsrapport 2014-Q3 |
| 2013-12-05 | - | Kvartalsrapport 2014-Q2 |
| 2013-10-01 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2013-09-06 | - | Kvartalsrapport 2014-Q1 |
| 2013-06-07 | - | Bokslutskommuniké 2013 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-03-01 | - | Kvartalsrapport 2012-Q3 |
| 2012-12-06 | - | Kvartalsrapport 2012-Q2 |
| 2012-09-25 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2012-09-24 | - | Årsstämma |
| 2012-09-06 | - | Kvartalsrapport 2012-Q1 |
| 2012-06-14 | - | Bokslutskommuniké 2011 |
| 2012-03-08 | - | Kvartalsrapport 2011-Q3 |
| 2011-12-08 | - | Kvartalsrapport 2011-Q2 |
| 2011-10-03 | - | X-dag ordinarie utdelning VIVE 0.00 SEK |
| 2011-09-30 | - | Årsstämma |
| 2011-09-08 | - | Kvartalsrapport 2011-Q1 |
| 2011-06-10 | - | Bokslutskommuniké 2010 |
| 2010-12-09 | - | Kvartalsrapport 2010-Q2 |
| 2010-09-24 | - | Årsstämma |
| 2010-09-09 | - | Kvartalsrapport 2010-Q1 |
| 2009-12-10 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
In accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB’s (”Vivesto”) Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023.
The Nomination Committee for the 2024 Annual General Meeting comprises the following members:
- Per Arwidsson, appointed by Arwidsro,
- Håkan Lagerberg, appointed by Mastan AB, and
- Peter Zonabend, Chairman of the Board of Vivesto.
Per Arwidsson has been appointed Chairman of the Nomination Committee.
Vivesto’s Annual General Meeting will be held on 23 May 2024.
Shareholders who wish to submit proposals to the Nomination Committee for the 2024 Annual General Meeting may send them by e-mail to nomination@vivesto.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting.
For further information, please contact:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a portfolio of projects with the potential to offer new treatment options for cancer patients with high unmet medical needs. The cancer program Cantrixil is being developed in the indications bladder cancer and blood cancer, and the veterinary oncology product Paccal Vet (paclitaxel micellar) is being developed for the treatment of malignant melanoma and hemangiosarcoma in dogs.
Vivesto has experience in developing drugs from the preclinical phase, through clinical development to regulatory approval. Vivesto's longest-developed program, Apealea® (paclitaxel micellar), has received market approval in the EU for the treatment of adult patients suffering from a first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer, in combination with carboplatin.
Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.